Dermavant Sciences, a subsidiary of Roivant Pharma, announced yesterday that it has named Frank Torti, MD and Myrtle Potter as directors, with Dr Torti named Chairman of the Board.
Dr Torti serves as Vant Investment Chair for Roivant Pharma. He earlier served as a partner at New Enterprise Associates. Prior to joining New Enterprise Associates in 2007, Dr Torti was a researcher at the Duke University Center for Clinical & Genetic Economics.
Potter serves as Vant Operating Chair for Roivant Pharma. She earlier served as Chief Executive Officer of Myrtle Potter & Company and President and Chief Operating Officer of Genentech. Prior to Genentech she was president of Bristol-Myers Squibb's US Cardiovascular and Metabolic business.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal